OBJECTIVE: To assess whether the contributions of individual metabolic syndrome components to coronary heart disease (CHD) risk vary in patients with different glucose tolerance. METHODS: A total of 1619 patients were included in this cross-sectional study. CHD, metabolic syndrome and glucose tolerance were assessed using coronary angiography, anthropometric and biochemical parameters, and an oral glucose tolerance test, respectively. Associations between CHD and components of metabolic syndrome were determined using logistic regression analysis. RESULTS: Low highdensity lipoprotein-cholesterol (HDL-C) was the only CHD risk factor in patients with both CHD and metabolic syndrome who had normal glucose tolerance, after adjustments for age, smoking and lowdensity lipoprotein-cholesterol (LDL-C) concentration. In patients with CHD plus metabolic syndrome and prediabetes, the most important risk factor was hypertension; additional risk factors were high postprandial blood glucose (PBG) and low HDL-C. In patients with CHD plus metabolic syndrome and diabetes, high PBG was the strongest risk factor, followed by hypertension, high FBG and high waist circumference. CONCLUSIONS: Individual components of metabolic syndrome contributed variously to CHD across different glucose tolerance statuses.
Introduction
Metabolic syndrome is a common and complex disease characterized by insulin resistance and increased cardiovascular risk. 1 Studies have examined the association between metabolic syndrome and increased risk of coronary heart disease (CHD), and have indicated a contributive and predictive role in CHD. 2, 3 The risk of morbidity and mortality from CHD are elevated among those with metabolic syndrome, 4 -6 with the risk of cardiovascular disease (CVD) increasing in line with the number of metabolic syndrome components present. 7, 8 Mortality from CVD has been shown to be 1.8-fold higher in men with metabolic KEY WORDS: METABOLIC SYNDROME; CORONARY HEART DISEASE; PREDIABETES; DIABETES MELLITUS a X Gong and X Pan contributed equally to this work. X Gong, X Pan, X Chen et al. Metabolic syndrome components and CHD syndrome, 9 and metabolic syndrome has been shown to be associated with a two-fold increase in the age-adjusted risk of fatal CVD in men and nonfatal CVD in women. 6 The components of metabolic syndrome do not, however, confer equivalent amounts of risk. 8 It is estimated that the number of adults with diabetes will increase to 300 million worldwide by 2025. 10 Among Chinese adults, age-standardized prevalences of prediabetes, diabetes and metabolic syndrome have been reported as 15.5%, 9.7% and 23.3%, respectively. 11, 12 It is estimated that 66% of patients with diabetes also have metabolic syndrome. 13 Diabetes mellitus is equivalent to CHD in terms of morbidity and mortality, 14 and this has significantly influenced guidelines for the treatment of diabetic complications. 15 Diabetes is consistently reported as one of the strongest predictors of adverse cardiovascular outcome, 16, 17 and has been shown to be associated with a more extensive disease burden and accelerated progression of atherosclerotic disease. 18 Diabetes mellitus is one of the components of metabolic syndrome, but few reports have compared the associations between CHD and individual metabolic syndrome components according to glucose tolerance status. This cross-sectional study of a Chinese population aimed to assess whether the contributions of individual metabolic syndrome components to CHD risk vary according to glucose tolerance status. Each patient's date of birth, medical history and smoking status were recorded; patients who reported smoking cigarettes or other tobacco products at least once a day for 1 year or more were considered to be smokers. Height, weight, waist circumference and seated blood pressure were measured, and body mass index (BMI) was calculated.
Patients and methods

PATIENTS
All patients provided written informed consent and the study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
CORONARY ANGIOGRAPHY
All patients underwent selective coronary angiography performed using the Judkins technique with multiple projections. A diagnosis of CHD was defined as ≥ 50% stenosis in at least one coronary artery segment. The severity of CHD was estimated using the Gensini score, 19 which is based on the degree of lumen narrowing, where a score of 1 represents 1 -25% narrowing; 2 represents 26 -50% narrowing; 4 represents 51 -75% narrowing; 8 represents 76 -90% narrowing; 16 represents 91 -99% narrowing; and 32 represents total occlusion. This score was then multiplied by a factor that took into account the importance of the lesion's position in the coronary arterial tree: 5 for the left main coronary artery; 2.5 for the proximal left anterior descending artery or proximal left circumflex artery; 1.5 for the mid-region of the left anterior descending artery; and 1 for the distal left anterior descending artery or mid-distal region of the X Gong, X Pan, X Chen et al. Metabolic syndrome components and CHD left circumflex artery. Gensini scores were adjusted for age, smoking status and lowdensity lipoprotein-cholesterol (LDL-C).
DIAGNOSIS OF METABOLIC SYNDROME
Venous blood samples were obtained from all participants early in the morning after a 10 -12 h fast. Blood was collected in sterile tubes containing 2 g/l sodium fluoride and plasma was isolated by centrifugation at 2000 g for 8 min at 4°C for the quantification of fasting blood glucose (FBG). For the quantification of total cholesterol, high-density lipoproteincholesterol (HDL-C), LDL-C and triglycerides, blood was collected in sterile tubes without anticoagulant, allowed to clot at room temperature for 1 h, and serum was isolated by centrifugation at 2500 g for 5 min at 4°C. Plasma and serum samples were stored frozen at -20°C until assayed. All parameters were quantified using enzymatic colorimetric assays (Architect ci8200 integrated system; Abbott Laboratories, Abbott Park, IL, USA).
Metabolic syndrome was diagnosed according to the modified Adult Treatment Panel III recommendations for Asian Americans. 20 A diagnosis of metabolic syndrome was made if patients had three or more of: (i) waist circumference ≥ 90 cm in males or ≥ 80 cm in females; (ii) triglycerides ≥ 1.7 mmol/l or on drug treatment for elevated triglycerides; (iii) HDL-C < 1.0 mmol/l in males or < 1.3 mmol/l in females or on drug treatment for low HDL-C; (iv) blood pressure ≥ 130/85 mmHg or on drug treatment for hypertension; and (v) FBG ≥ 5.6 mmol/l or on drug treatment for diabetes mellitus.
GLUCOSE TOLERANCE STATUS
All patients without a history of diabetes underwent a 2-h 75 g oral glucose tolerance test (OGTT) early in the morning before angiography.
Plasma glucose was quantified as described above. Results were evaluated according to American Diabetes Association criteria for type 2 diabetes. 21 Prediabetes was defined as a FBG of 5.6 -< 7.0 mmol/l and/or a postprandial blood glucose (PBG) after the OGTT of 7.8 -< 11.1 mmol/l. Diabetes was defined as FPG of ≥ 7.0 mmol/l and/or a PBG of ≥ 11.1 mmol/l. For patients with previously diagnosed diabetes, PBG was determined 2 h after eating breakfast.
STATISTICAL ANALYSES
The mean ± SD for the data were calculated. Differences in measured parameters were analysed using the χ 2 -test for categorical variables and analysis of variance for normally distributed continuous variables. Logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) after adjustments for age, smoking status and LDL-C. A Pvalue < 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS ® version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results
A total of 1619 patients (mean age 64.05 ± 10.07 years) were enrolled into the study and divided into three groups according to the presence or absence of CHD and metabolic syndrome. A total of 568 patients were diagnosed with both CHD and metabolic syndrome (CHD + MetS group; 222 with normal glucose tolerance, 132 with prediabetes and 214 with diabetes); 675 patients were diagnosed with CHD without metabolic syndrome (CHD only group; 439 with normal glucose tolerance, 128 with prediabetes and 108 with diabetes); and 376 X Gong, X Pan, X Chen et al. Metabolic syndrome components and CHD patients did not have CHD and were used as the control group (218 with normal glucose tolerance, 88 with prediabetes and 70 with diabetes). There were statistically significant differences in the proportions of patients with normal glucose tolerance, prediabetes and diabetes across the three groups (P < 0.01). The demographic and anthropometric characteristics and biochemical parameters of all the study participants are given in Table 1 .
Mean age, percentage of smokers and LDL-C concentration were significantly higher in all patients with CHD compared with controls (P < 0.05 for all comparisons; Table 1 ). Waist circumference and systolic blood pressure were significantly higher and HDL-C was significantly lower in patients with CHD + MetS with prediabetes or diabetes than in patients with CHD alone (P < 0.05 for all comparisons; Table 1 ). Of the patients with CHD + MetS, those with diabetes had a significantly higher waist circumference, BMI, systolic blood pressure, blood glucose (FBG and PBG) and triglyceride levels than those with normal glucose tolerance (P < 0.05 for all comparisons; Table 1 ).
The number of diseased vessels and the Gensini score, after adjustment for age, smoking status and LDL-C concentration, in patients with CHD alone and in patients with CHD + MetS stratified according to glucose tolerance are shown in Table 2 . Patients in all three CHD + MetS groups had significantly more diseased vessels and a higher Gensini score than patients with CHD alone (P < 0.05 for all comparisons). Within the CHD + MetS group, the number of diseased vessels and Gensini score were significantly higher in prediabetes and diabetes patients than in those with normal glucose tolerance (P < 0.05 for all comparisons).
Associations between CHD and the individual components of metabolic syndrome in patients with CHD + MetS according to the different glucose tolerance statuses were analysed after adjustment for age, smoking and LDL-C level ( Table 3) . For patients with normal glucose tolerance, low HDL-C was the only risk factor for CHD. In those with prediabetes, hypertension, high PBG and low HDL-C were shown to be risk factors for CHD. For patients with diabetes, a high PBG was the most important risk factor for CHD; other risk factors included hypertension, high FBG, low HDL-C and high waist circumference.
Discussion
Metabolic syndrome is characterized by the presence of multiple cardiovascular risk factors including abdominal obesity, dyslipidaemia, elevated glucose levels and elevated blood pressure. 22 Increased prevalence of CVD in metabolic syndrome has been shown to be related to glucose status, 23 and individual components of metabolic syndrome have been found to make different contributions to CHD. 8 Although several studies have evaluated the associations between metabolic syndrome, diabetes and coronary atherosclerosis, 24 -27 the impact of individual components of metabolic syndrome on CHD in patients with different glucose tolerance statuses has not been previously studied. Since CHD is the most important aspect of CVD, the present cross-sectional study in a Chinese population assessed whether individual components of metabolic syndrome were related to the risk of CHD in patients with different glucose tolerances.
There is a close relationship between diabetes and coronary atherosclerosis, with studies confirming that a higher cardiovascular risk is associated with X Gong, X Pan, X Chen et al. 
Metabolic syndrome components and CHD
TABLE 1 Demographic, anthropometric and biochemical parameters in patients with coronary heart disease and metabolic syndrome
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impaired glucose regulation. 28 A high PBG, indicating prediabetes or diabetes, was found to be predictive of CHD in the present study, suggesting that the pathological changes of CHD may be more severe in metabolic syndrome patients with diabetes or prediabetes.
It has been shown that HDL-C is the only lipoprotein to prevent atherosclerosis, and that low HDL-C is a risk factor for CHD. Robust evidence for this was provided by the Emerging Risk Factors Collaboration. 29 This analysis of 68 studies, that included 302 430 participants without prior history of CVD, found that HDL-C was strongly associated with coronary risk even after adjustment for non-HDL-C, triglycerides and nonlipid risk factors. 29 Other studies, however, have demonstrated no relationship between plaque size or a lipid-rich necrotic core and HDL-C. 30, 31 A low HDL-C level was a risk factor for CHD in both diabetic and nondiabetic patients in the present study, and was the only risk factor for CHD in The relationship between triglyceride concentration and vascular disease is uncertain. In patients with type 2 diabetes mellitus, marked atherogenic dyslipidaemia (triglycerides ≥ 2.3 mmol/l) and low HDL-C levels (≤ 0.88 mmol/l) were associated with a 30 -70% increase in CVD event rates compared with those without this profile. 32 Triglyceride concentration was significantly higher in CHD + MetS patients with diabetes than in patients with normal glucose tolerance in the present study, but high triglyceride concentration was not a risk factor for CHD. This finding is consistent with the results of other studies. 33 Further studies are required in order to clarify the relationship between triglyceride concentration and CHD.
Several studies have found a large variance in risk factors for cardio-and cerebrovascular disease amongst the individual components of metabolic syndrome. 34, 35 The present study confirmed this variance for CHD across different glucose tolerance statuses in patients with metabolic syndrome. Hypertension was the strongest risk factor in CHD + MetS patients with prediabetes, followed by high PBG and low HDL-C. The number of metabolic syndrome components that were risk factors for CHD was highest in CHD + MetS patients with diabetes, including high PBG, hypertension, high FBG, low HDL-C and high waist circumference.
In conclusion, the present study has demonstrated that the individual components of metabolic syndrome contribute differently to risk of CHD in different glucose tolerance statuses. Tailoring interventions to prevent CHD in patients with metabolic syndrome according to glucose tolerance status may have important clinical significance.
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